$2500 | Single User
$5000 | Site License
$7500 | Global License

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018
[Report Updated: 28-02-2018]

Published by Global Data: 28 Feb 2018 | 211035 | In Stock
Related Topics: Clinical Trials , Multiple Myeloma , Myeloma

Introduction

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 5

    Report Guidance 6

    GlobalData Clinical Trials Report Coverage 7

    Clinical Trials by Region 8

    Clinical Trials and Average Enrollment by Country 9

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

    Top Five Countries Contributing to Clinical Trials in Europe 12

    Top Countries Contributing to Clinical Trials in North America 13

    Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

    Top Five Countries Contributing to Clinical Trials in Central and South America 15

    Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 16

    Clinical Trials by Phase in G7 Countries 17

    Clinical Trials in G7 Countries by Trial Status 18

    Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 19

    Clinical Trials by Phase in E7 Countries 20

    Clinical Trials in E7 Countries by Trial Status 21

    Clinical Trials by Phase 22

    In Progress Trials by Phase 23

    Clinical Trials by Trial Status 24

    Clinical Trials by End Point Status 25

    Subjects Recruited Over a Period of Time 26

    Clinical Trials by Sponsor Type 27

    Prominent Sponsors 28

    Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials 30

    Prominent Drugs 31

    Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) 32

    Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 32

    Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 32

    Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting 33

    Jan 16, 2018: Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma 33

    Jan 08, 2018: Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma 34

    Jan 02, 2018: Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma 34

    Dec 21, 2017: BioLineRx Announces Initiation of Phase III GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients 35

    Dec 18, 2017: Poseida Therapeutics Announces First Patient Treated in Phase I Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients With Multiple Myeloma 35

    Dec 12, 2017: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible 36

    Dec 12, 2017: Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies 36

    Dec 12, 2017: Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple 37

    Dec 11, 2017: PharmaMar shows new data on plitidepsin for the treatment of multiple myeloma at ASH annual meeting 38

    Dec 11, 2017: TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology 38

    Dec 11, 2017: New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma 38

    Dec 11, 2017: Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study 40

    Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017 40

    Dec 10, 2017: Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting 41

    Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 42

    Dec 07, 2017: Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342 42

    Dec 07, 2017: Sanofi explores combination treatments for multiple myeloma in new late-stage trials 42

    Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma 43

    Nov 29, 2017: Bristol-Myers Squibb to Present New Data on Multiple Myeloma Drug Elotuzumab at the 59th Annual Meeting & Exposition of the American Society of Hematology 43

    Nov 29, 2017: Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform 44

    Clinical Trial Profile Snapshots 46

    Appendix 1553

    Abbreviations 1553

    Definitions 1553

    Research Methodology 1554

    Secondary Research 1554

    About GlobalData 1555

    Contact Us 1555

    Disclaimer 1555

    Source 1556

List Of Tables
in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

List of Tables

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2018* 8

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018* 19

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2018* 22

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31

List Of Figures, Charts and Diagrams
in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

List of Figures

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018* 19

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23

Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30

Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31

GlobalData Methodology 1554

Additional Details

Publisher

Global Data

Publisher Information

Reference

211035 | GDHC4814CTIDB

Number of Pages

1556

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...